Ginger: properties, clinical integration, and role in key metabolic pathways

In the literature dedicated to inflammatory diseases and chronic conditions, ginger is described as a substance capable of interacting with transversal biological processes. This interest stems from its phytochemical composition, especially gingerols and shogaols, two bioactive compounds that can influence signaling pathways related to oxidative stress, immune response, and cellular metabolism. A review on inflammatory diseases highlighted the potential of ginger compounds in reducing pro-inflammatory signals and interfering with pathways involving NF-kB, a transcriptional platform that regulates the production of many cytokines [10]. In parallel, a meta-analysis on inflammatory markers showed, in available RCTs, a reduction in CRP, hs-CRP, and TNF-a, albeit without a significant effect on IL-6 and sICAM; this detail is important because it suggests selective modulation, not a generalized suppression of inflammation [3]. In a broader perspective, a 2021 review synthesized the numerous fields of interest of ginger bioactives, linking antioxidant, inflammatory, and metabolic activity [11].

A relevant chapter concerns cancer prevention. A specific review on ginger and its purified components described a chemopreventive rationale based on the modulation of inflammation, control of proliferation, and interference with the survival of transformed cells [12]. These actions are consistent with an effect on factors that promote tissue instability and neoplastic progression. A recent review on colorectal carcinoma also reiterated that ginger compounds, especially gingerols and shogaols, act on multiple steps of the tumor microenvironment and signaling pathways, but largely on a preclinical basis [13]. In this area, it is useful to avoid any overinterpretation: the fact that the same compound influences pathways involved in cell growth does not equate to proof of clinical antitumor efficacy in humans. For this reason, the correct message remains one of promising biological interest, not an alternative treatment. Caution is also essential because the oncological context requires hard endpoints, adequate follow-up, and comparison with established standards, elements that are currently lacking in most studies on ginger and carcinogenesis [13][12].

The intestinal dimension is equally important. A review dedicated to inflammatory bowel diseases described the possible role of ginger and its constituents in supporting the epithelial barrier and reducing certain inflammatory signals [14]. The intestinal barrier, in fact, is not just a mechanical filter: it regulates the passage of antigens, microbes, and mediators that can fuel systemic inflammation. In cellular models, 6-shogaol, a shogaol characterized by particularly studied biological activity, has shown the ability to prevent TNF-a-induced barrier loss by inhibiting PI3K/Akt and NF-kB [15]. This is interesting because it links the intestinal environment with intracellular pathways that regulate permeability, inflammation, and immune response. A coherent picture emerges: ginger appears biologically plausible in chronic conditions where persistent inflammation represents a central issue, but human evidence is not yet sufficient to generalize its use as a specific therapeutic intervention [13][12][10][14][15].

The overall picture must be read with precision. The evidence is more convincing when discussing inflammatory modulation and biochemical signals; it becomes weaker when direct clinical applications in oncology or intestinal pathologies are claimed. Precisely this distinction allows ginger to be used in correct scientific language, separating the rationale from the therapeutic claim. This leads to the natural connection with more specific intracellular mechanisms, where the relationship with mTOR, the protein complex that integrates growth signals and energy availability, becomes central [13][12][10][14]. An institutional interpretation must therefore value biological plausibility without transforming it into an indiscriminate clinical recommendation. In summary, ginger deserves attention as a nutritional adjuvant, especially in conditions where inflammation, oxidative stress, and barrier dysfunction contribute to pathophysiology [11][10][3].

Areas that deserve attention include:

• interaction with systemic and local inflammation;
• possible role in cancer prevention processes;
• connections with intestinal health and the gut microbiota, i.e., the community of microorganisms living in the intestine;
• applications in chronic metabolic diseases;
• prudent interpretation of available human data [13][12][10][14][3].

Among ginger's bioactive compounds, 6-shogaol is the compound most directly linked to the regulation of the PI3K/AKT/mTOR axis, an intracellular signaling cascade that controls cell growth, survival, and metabolism. In cervical cancer cell models, this metabolite has shown an antitumor effect, associated with a reduction in cell growth through the PI3K/Akt/mTOR pathway [16]. Another review, dedicated to the antitumor properties of 6-shogaol, summarized its role in modulating proliferation, apoptosis (i.e., programmed cell death), and survival signals, confirming that its interest stems from a multifactorial action rather than a single target [17]. In oral cancer, 6-shogaol also showed an anticancer effect associated with the suppression of the AKT signal, a kinase, i.e., an enzyme that transfers phosphate groups and transmits intracellular signals [18]. This convergence of data suggests that ginger may act on a shared regulatory network rather than a single molecular anomaly. Biologically, this data is relevant because many cancers and inflammatory conditions depend precisely on overly persistent survival signals.

The significance of mTOR, however, extends beyond oncology. mTORC1, i.e., mTOR protein complex 1, integrates nutrients and growth factors to promote protein synthesis and anabolism, which is the set of processes that build new cellular molecules; when this pathway is excessively active, the cell tends to remain in a state of growth and reduce the turnover of damaged components. In this context, the modulation of mTOR by ginger compounds is interpreted as a possible advantage in contexts of chronic inflammation, metabolic stress, and altered cellular quality [16][17]. The connection with autophagy, the system by which the cell degrades and recycles damaged internal components, is particularly important. When mTOR is inhibited, this process can become more active and promote homeostasis, i.e., the maintenance of internal balance. Ginger is, therefore, observed as a potential modulator of the balance between cellular growth and maintenance, a central balance in many chronic diseases [19][15].

Preclinical literature also suggests a possible interaction with AKT and PI3K, i.e., with the initial enzyme of the cascade, which amplifies the survival and growth signal. 6-shogaol reduced the PI3K/Akt signal in intestinal barrier models, helping to preserve epithelial integrity against TNF-a, a tumor necrosis factor involved in inflammation [15]. This data reinforces the idea that ginger does not act only on a single disease, but on a set of shared pathways that govern proliferation, inflammation, and stress response. The same logic is found in other ginger compounds, but 6-shogaol remains the clearest reference for understanding the relationship with mTOR [16][18][17][15]. In parallel, other research on ginger and its constituents shows effects on energetic and redox pathways, i.e., on oxidation-reduction balance systems, which can converge on the control of cell growth, making the overall picture coherent [19][20][21][22][23].

For the reader, the practical conclusion is simple: the relationship between ginger and mTOR is one of the most solid points in experimental literature, but it remains a biological rationale. Clinical translation in humans, especially outside oncology, is not demonstrated with the same strength. Hence the natural transition to energy regulation mechanisms, where AMPK, a kinase sensitive to cellular energy status, and mTOR are seen as two sides of the same metabolic balance [16][17][15]. In this scenario, clinical evidence on ginger in other domains, such as glycemia and inflammation, helps to understand why its profile is considered promising even when the final outcome does not directly concern mTOR [1][2][4][10][24][25].

Overall, the scientific message remains cautious but clear. 6-shogaol represents a credible bridge between phytochemistry and cell signaling biology. However, its ability to modulate PI3K/AKT/mTOR should not be confused with a therapeutic effect already validated in humans. At present, the most robust data is that ginger offers a coherent mechanistic rationale, useful for interpreting future studies and for connecting metabolism, inflammation, and cellular adaptation within a single pathophysiological framework [16][18][17][15].

The most relevant biological junctures to follow are these:

• activation or inhibition of the PI3K/AKT/mTOR pathway;
• effects on cell proliferation and survival;
• possible interference with autophagy and oxidative stress, i.e., the alteration due to an excess of reactive oxygen species;
• connections between mTOR, inflammation, and the tissue microenvironment;
• primarily preclinical value of available observations [16][18][17][19][15].

One of the most interesting aspects emerges from studies on 6-gingerol in skeletal muscle cells [11]. In cellular models, this compound increased AMPKa2 phosphorylation, i.e., the addition of a phosphate group that reflects its functional activation, leading to an increase in cellular glucose uptake [19]. In another study on C2C12 cells, a ginger extract increased GLUT4 expression, the glucose transporter, mainly through AMPK rather than PI3K, phosphatidylinositol 3-kinase involved in insulin signal transduction [27]. These observations are important because they show a mechanism consistent with increased glucose uptake in muscle, a crucial tissue for glycemic control [19,27]. From a pathophysiological point of view, skeletal muscle is indeed the main peripheral site of glucose utilization after meals, and its insulin resistance is one of the cornerstones of type 2 diabetes. When AMPK is activated, the cell interprets a condition of limited energy availability and responds by promoting the entry of substrates and optimizing their use. Ginger therefore seems to act on a regulatory node that connects energy signal, glucose transport, and insulin sensitivity, with a biological plausibility that goes beyond the symptomatic effect.

The connection with lipid metabolism is equally solid on an experimental level. In rats fed a high-fat diet, 6-gingerol attenuated the AMPK-NF-kB axis, i.e., the circuit that relates the energy sensor to nuclear factor kappa B, reducing inflammatory signals and improving the metabolic profile [21]. In a murine model of hepatic steatosis, i.e., fat accumulation in the liver, 6-gingerol reduced lipid accumulation, inflammation, and oxidative stress through the activation of LKB1/AMPK, a pathway that connects an upstream kinase to cellular energy regulation [23]. Even more specifically, a mix of phenolic compounds from ginger improved mitochondrial function, activated AMPK, and reduced lipid accumulation in adipocytes, cells specialized in fat storage [22]. These results are biologically convergent: when AMPK is activated, the cell tends to reduce lipid anabolism and improve energy efficiency, with favorable effects on the liver, muscle, and adipose tissue [21,22,23]. In other words, the axis does not only act on glucose, but on the entire balance between energy deposition and consumption. This is particularly relevant in metabolic syndrome, where low-grade inflammation, steatosis, and insulin resistance reinforce each other.

The transition from AMPK to mTOR thus becomes readable as an energy rebalancing. AMPK can inhibit mTORC1, the mTOR complex that promotes cell growth, through intermediate steps involving the control of energy availability and the activation of upstream regulatory nodes. In functional terms, this favors processes such as autophagy, i.e., the intracellular recycling of damaged components, less oxidative stress, and better management of energy substrates. This scheme is also well illustrated by studies on other natural compounds that modulate AMPK and mTOR in muscle or liver cells [28,29,30,31]. The interest of ginger lies in the fact that its components seem to fit into the same biological architecture, with a consistency that spans multiple experimental models [19,21,22,23]. Clinically, less pressure on mTOR can be useful when nutritional excess constantly keeps anabolic and pro-inflammatory pathways active. For this reason, the most correct interpretation is not that of an "anti-growth" effect, but of a rebalancing of the relationship between energy availability, cellular repair, and nutrient utilization.

The conceptual core is therefore clear: ginger is not simply a "hypoglycemic" substance, but a modulator of broader energy networks. AMPK activation helps explain why the results observed in some human studies are accompanied by improvements in glycemia, insulin sensitivity, and lipid profile. However, the distance between preclinical and clinical remains real, and precisely for this reason, the picture should be read as a strong biological rationale, not as definitive proof of metabolic efficacy in humans [19,21,22,23,27]. In institutional practice, this means valuing the mechanism without overestimating the transferability of experimental data. When diet, weight control, physical activity, and therapy are integrated, the possible modulation of AMPK by ginger can represent a complementary, not substitute, piece in metabolic risk management.

To read this axis in an orderly manner, it is advisable to follow three levels: the first concerns the energy stress signal that activates AMPK; the second includes the regulation of mTOR and autophagy processes; the third is observed in target tissues, especially muscle, liver, and adipocytes. From this perspective, the bioactive profile of ginger appears consistent with its discussion in the literature on glycemia, lipids, and inflammation [19,21,22,23,27].

• AMPK activation as an energy stress signal;
• effects on mTOR, autophagy, and glucose utilization;
• impact on muscle, liver, and adipose tissue;
• connection with clinical biomarkers observed in trials [19,21,22,23,27].

In clinical trials, ginger has been primarily evaluated for its potential impact on insulin sensitivity, meaning the ability of tissues to respond effectively to insulin. In this context, it's important to remember that insulin resistance is not just a laboratory number, but a defect in the response of peripheral tissues to the insulin signal. When muscle, liver, and adipose tissue respond less effectively, the pancreas compensates with hyperinsulinemia, i.e., an increase in circulating insulin, while glycemia tends to rise and metabolic risk increases. In some studies on subjects with metabolic alterations, supplementation reduced circulating insulin and HOMA-IR, the index that estimates insulin resistance based on fasting glycemia and insulinemia [1][2]. In the type 2 diabetes study, 3g per day for 3 months led to a significant drop in glycemia, HbA1c (glycated hemoglobin, which reflects the average glycemia over the preceding months), and insulin resistance, while the subsequent trial also observed an improvement in the oxidative profile [1][2]. These results are relevant because they indicate a possible effect on multiple levels of the pathology, not just on surface glycemia. Ginger is therefore observed as a metabolic adjuvant, not as a substitute for therapy, and its usefulness depends primarily on the clinical context in which it is used.

The consistency of the signal emerges more clearly in cases of metabolic syndrome and obesity, two conditions in which insulin resistance is often accompanied by chronic low-grade inflammation, i.e., a persistent but mild activation of inflammatory processes. In a randomized study on subjects with metabolic syndrome, 3g per day for 8 weeks improved several anthropometric parameters (body measurements like weight and circumference) and metabolic parameters, including fasting glycemia [5]. In obese patients with newly diagnosed T2DM, ginger supplementation improved glycemic control and the lipid profile, meaning the distribution of circulating fats [6]. A meta-analysis, a quantitative synthesis of multiple studies, on overweight or obese subjects found overall improvements in metabolic profiles, albeit with variable intensity [7]. The pathophysiological interpretation remains consistent: when chronic hyperinsulinemia fuels inflammation and oxidative stress, a nutritional modulator that acts on multiple levels can help break part of the vicious cycle [7][32][9]. In this sense, the effect should not be interpreted as a simple "sugar lowering," but as a possible attenuation of a biological environment that hinders insulin action.

A further important element concerns the inflammatory and redox component, a term indicating the balance between oxidizing processes and antioxidant defenses. In one of the trials on type 2 diabetes, in addition to glycemia, HbA1c, insulin, and HOMA-IR, hs-CRP (high-sensitivity C-reactive protein, which signals systemic inflammation), PON-1 (an enzyme associated with lipoprotein protection), TAC (total antioxidant capacity), and MDA (a marker of lipid peroxidation) improved [2]. This data is important because insulin resistance is closely intertwined with the activation of pro-inflammatory pathways and the accumulation of reactive oxygen species, oxidizing molecules produced during metabolism. In this scenario, the reduction of hs-CRP signals a lower systemic inflammatory response, while the increase in PON-1 and TAC suggests a strengthening of antioxidant defenses. Finally, the decrease in MDA indicates a containment of lipid peroxidation, one of the main markers of oxidative membrane damage [2][4][11]. For this reason, the clinical data are compatible with a broader biological action, which also involves the cellular microenvironment in which insulin resistance develops. Available reviews indeed emphasize that ginger's action is not limited to carbohydrate metabolism but affects inflammation, oxidative homeostasis, and energy signals [4][11][9].

Another area of interest is non-alcoholic fatty liver disease (NAFLD), which is the accumulation of fat in the liver not caused by alcohol. In a randomized, double-blind, placebo-controlled clinical study on patients with T2DM and NAFLD, ginger intervention improved metabolic parameters and the picture of fatty liver disease [32]. This result is particularly interesting because it links the metabolic benefit to hepatic pathophysiology, where insulin resistance promotes lipid accumulation, lipotoxicity (toxicity due to excess fats), and oxidative stress. In the insulin-resistant liver, fatty acid uptake and oxidation become inefficient, while lipid synthesis can remain inappropriately active. In such a context, a nutritional intervention capable of reducing oxidative load and improving energy signaling can have a concrete clinical impact. The summary evidence is reinforced by a meta-analysis that examined the effects of ginger on T2DM and components of metabolic syndrome, reporting a favorable but not uniform signal across all endpoints [9]. This aspect calls for interpretive caution but does not weaken the rationale; rather, it defines a realistic scope of use, where the benefit is more plausible in subjects with already manifest metabolic dysfunction.

The central point, therefore, is that ginger seems to work better when the initial problem is already present. In these cases, its action on the inflammatory network (the set of biological pathways involved in inflammation), oxidative stress, and energy signals can translate into a measurable improvement in parameters such as HOMA-IR, insulin, and glycemia. Biological plausibility is also supported by experimental studies showing involvement of AMPK (a kinase that regulates cellular energy balance), mTOR (a regulator of growth and metabolism), and pathways related to carbohydrate and lipid metabolism [19][20][21][22][23]. This does not eliminate the limitations of the literature but helps to place the compound in its correct space: a nutritional adjuvant with a biological rationale, especially in metabolic disorders [1][2][4][11][5][6][7][32][9].

The following points delve into the most relevant clinical data and the contexts in which the signal appears strongest. The goal is to understand when the improvement in insulin resistance is truly observable and when it remains only a biological hypothesis.

The question of ginger and fasting glycemia is among the most frequent, because it addresses a very concrete need: to understand whether a spice can contribute to blood sugar control. In trials on T2DM, i.e., type 2 diabetes mellitus, supplementation with 3 g per day for 3 months significantly reduced serum glycemia, with a decrease of 19.41 ± 18.83 mg/dL in the study by Mozaffari-Khosravi and a similar improvement in the study by Arablou [1][2]. In both cases, the signal does not concern a single parameter, but a constellation of metabolic indices that move together. The same literature reports improvements in HbA1c, insulin, and insulin resistance, i.e., the reduced ability of tissues to respond to insulin, with consistent effects also on hs-CRP, high-sensitivity C-reactive protein, PON-1, paraoxonase 1, TAC, total antioxidant capacity, and MDA, malondialdehyde, in Arablou's study [2]. This is important because it suggests an action that spans glycemic control, oxidative stress, and low-grade inflammation. The 2018 meta-analysis on T2DM and components of metabolic syndrome confirmed a favorable signal on glycemia, while noting the heterogeneity of the protocols [9]. It is therefore more correct to speak of metabolic support than autonomous therapy. Ginger does not replace diet, physical activity, and medications, but can support standard strategies when the goal is to improve the quality of glycemic control.

Post-prandial metabolism is crucial because it coincides with the moment when the body must manage the intake of nutrients after a meal. In this context, a randomized study in 24 non-diabetic adults tested 100 mL of aqueous ginger extract containing 0.2 g/100 mL and observed a significant reduction in the incremental area under the curve, i.e., iAUC, of glucose and the maximum post-prandial concentration [8]. This data is relevant because it shows that the effect is not limited to fasting glycemia, but can affect the dynamics with which glucose is managed after ingestion. From a pathophysiological point of view, post-prandial peaks are closely linked to cardiometabolic risk, especially when associated with hyperinsulinemia and inefficient peripheral clearance, i.e., a slowed removal of glucose from the blood by tissues. A slight but repeatable modulation of these peaks can have clinical value, particularly in subjects with prediabetes, obesity, or early type 2 diabetes. The correct interpretation requires precision: it is not a "block" of absorption, but a possible modulation of the overall metabolic response, probably mediated by combined effects on insulin secretion, tissue sensitivity, and hepatic glucose management.

In physiological terms, all this is linked to peripheral glucose uptake and the function of cellular transporters, particularly GLUT4, the main glucose transporter in muscle cells in response to insulin and energy pathways [36][37][38]. Skeletal muscle is the main tissue responsible for glucose clearance after a meal; when GLUT4 is correctly translocated to the membrane, glycemia tends to be better managed [37][39][40]. In experimental models, ginger compounds seem to favor this dynamic through AMPK, adenosine monophosphate kinase, and AS160, a regulatory protein of GLUT4 trafficking [19][41][42][27]. This step is central: AMPK functions as an energy sensor and, when activated, directs the cell towards a more efficient use of glucose and energy substrates. In parallel, the regulation of AS160 facilitates GLUT4 translocation and makes the muscle's response to insulin more prompt. It is therefore not a single target, but a network of signals that integrates metabolism, energy availability, and response to oxidative stress. This is where ginger fits in a biologically plausible way, especially in contexts where insulin resistance alters the normal distribution of glucose between the liver, muscle, and adipose tissue.

Overall, therefore, the literature suggests that ginger can contribute to better carbohydrate regulation both fasting and after meals. The picture remains more convincing in subjects with initial metabolic alterations, but the biological rationale also extends to the physiology of glucose uptake. This helps to correctly interpret the results: the benefit is neither universal nor the same for everyone, but emerges with greater consistency when the metabolic system is already under stress. Hence the natural transition to daily use and practical consumption methods, which help translate data into realistic eating behavior [1][2][9][19][41][27][8].

The most frequent questions focus on:

• control of fasting and post-prandial glycemia;
• role in glucose transport and utilization;
• differences between food and supplemental use;
• interest in subjects with metabolic alterations;
• interpretation of glycemic peaks after meals [1][2][9][8].

Fresh ginger and powdered ginger are not practically equivalent, as they differ in format, concentration, and usage. In clinical trials, i.e., experimental studies conducted on humans, the most common form used has been powder in capsules, often at a dose of 3 g per day for 8-12 weeks or 3 months, as in studies on diabetes, metabolic syndrome, and obesity [1][2][5][6][9]. This choice is not random, because powder allows for better standardization, which is useful when comparing the effect of gingerols and shogaols on glycemia, inflammation, and metabolism. Gingerols and shogaols are bioactive compounds, meaning substances naturally present in ginger and responsible for some of its biological activities. In a food context, however, the chosen form depends mainly on aroma, ease of use, and tolerability. Fresh ginger is more versatile in cooking, while powder is simpler to dose. The most useful aspect is to understand that the selected form must be consistent with the dietary goal, tolerability, and ease of adherence over time. This also applies when seeking use oriented towards metabolic support, because the effect depends on continuity, not on a single use.

The dose is a crucial point, because what has been studied clinically does not always coincide with spontaneous consumption in the diet. In trials, the quantity of 3 g per day has repeatedly emerged as an operational reference [1][2][5][6]. In patients with type 2 diabetes, for example, 3 g/d for 3 months led to reductions in glycemia, HbA1c, insulin, and HOMA-IR compared to placebo in 41 patients, 22 in the ginger group and 19 in the placebo group [1]. HbA1c, or glycated hemoglobin, reflects the average trend of glycemia in the preceding weeks. HOMA-IR is an index of insulin resistance, thus estimating how difficult the body responds to insulin. Another study, also with 3 g/d for 3 months in adults with T2DM, observed improvements in glycemia, HbA1c, insulin, insulin resistance, hs-CRP, PON-1, TAC, and MDA [2]. Hs-CRP is high-sensitivity C-reactive protein, an indicator of systemic inflammation. PON-1, or paraoxonase-1, is an enzyme associated with protection from oxidative stress. TAC, or total antioxidant capacity, indicates the overall potential for defense against free radicals. MDA, or malondialdehyde, is a marker of lipid peroxidation, thus signaling oxidative damage to lipids. These data suggest a clinical interest especially for metabolic and oxidative control, but do not define a universal dose. For daily use, there is no single threshold, because culinary habits, individual sensitivity, and dietary context vary greatly. The key message is that continuity of use, if desired, matters more than occasional intensity, especially when it comes to daily nutrition. In other words, moderate and regular use is more realistic than sporadic and concentrated use. In prevention pathways, this aspect is also important so as not to overload the diet with expectations disproportionate to the available data.

The distinction between food use and supplementary use also remains important. Ginger in cooking provides a different and less standardized quantity of bioactive compounds compared to capsules or extracts, so it should not be equated with clinical protocols. This does not mean it is useless, but that it should be read as part of a broader dietary pattern, i.e., a coherent set of food choices. The same applies to beverages or infusions: they can be practical and well-accepted, but they do not replace controlled studies. Clinical literature and reviews suggest that effects on metabolism, lipids, and inflammation emerge more clearly when the product is well-characterized and taken regularly [4][11][24]. For those seeking practical guidance, the best criterion is consistency with one's personal diet, not the search for an immediate effect [1][2][5][6][8]. In this sense, the dietary use of ginger should be interpreted as realistic support, not as an isolated intervention. The more consumption is part of an overall balanced diet, the more plausible it is that it integrates with the benefits observed in trials on glycemic control, oxidative stress, and systemic inflammation.

In summary, the most correct way to use ginger in your routine is to choose the most manageable form, maintain a reasonable quantity, and not attribute properties to it that are independent of lifestyle. The link to safety is immediate: the more concentrated the form, the greater the need to evaluate tolerability and individual context [1][2][5][6]. This caution is particularly relevant in pregnancy, where institutional recommendations consider ginger as a possible option for nausea, but always within an appropriate clinical framework [34][35]. Even outside of pregnancy, the logic remains the same: simple use, reasonable dose, clear objective, and attention to personal response. This way, ginger becomes a plausible functional food, not a therapeutic shortcut.

To organize daily use correctly, consider:

• food forms and differences in use;
• indicative quantities and frequency of consumption;
• common errors in home preparation;
• compatibility with habits and nutritional goals;
• difference between culinary use and clinical studies [1][2][5][6][8].

The safety of ginger has been examined with particular attention during pregnancy, a period when the balance between expected benefit and clinical prudence becomes more delicate. The World Health Organization guideline lists ginger among the recommended options for nausea relief in early pregnancy, along with other possibilities, based on the woman's preferences and available options [34]. The NIH professional fact sheet, however, emphasizes that during pregnancy, botanicals, i.e., plant-derived products used for health purposes, require caution due to possible safety concerns [35]. This dual reference is very useful because it shows a precise point of balance: ginger can play a symptomatic role in some contexts, but this does not automatically make it appropriate in every clinical situation or at any dose [34][35]. In other words, potential efficacy does not eliminate the need to evaluate exposure, duration, and patient vulnerability.

Outside of pregnancy, tolerability primarily depends on individual sensitivity. In general, the food is well-accepted, but high concentrations or extracts can be associated with gastrointestinal disturbances, meaning stomach and intestinal discomfort, in susceptible individuals. The literature on inflammatory diseases and intestinal processes helps contextualize this observation, because ginger interacts with the intestinal barrier, which is the defense system of the mucosa, and with mucosal inflammation, meaning inflammation of the inner surface of the intestine; therefore, it is reasonable to expect differences in response based on the initial state [14][15]. The form of intake also matters: moderate dietary use is not equivalent to a concentrated supplement. For this reason, the perception of "naturalness" should not be confused with the absence of risk. On a pathophysiological level, meaning the altered functioning of tissues and organs, an already irritated mucosa, an altered gut microbiota, or increased visceral reactivity, meaning of the intestine and internal organs, can make effects more evident that remain minimal or absent in other subjects.

Another important element is the presence of concomitant therapies, meaning treatments taken during the same period, or specific clinical conditions. Although the material available in this article is more robust regarding metabolic and pregnancy aspects, the principle of prudence remains valid when ginger is used as a supplement rather than a simple spice. In any at-risk situation, the decision should always be brought back to the individual context. Safety, therefore, does not contradict the potential benefit: it completes it, because it allows us to understand where use is plausible and where greater caution is needed [34][35][14]. This is particularly relevant when ginger is used alongside medications or complex therapeutic plans, where even a modest effect on tolerability or metabolism can have significant clinical repercussions.

The final message is that ginger can be useful, but it should be treated as a biologically active substance, not as a neutral ingredient. The distinction between daily food, extract, and supplement is crucial for correctly interpreting data and applying them without oversimplification. This leads to the connection with the topic of evidence quality, which helps distinguish the scientific signal from widespread expectation [34][35][14]. Furthermore, the same antioxidant and anti-inflammatory properties that support the clinical interest in ginger also explain why the safety profile must be interpreted in the context of dose and host vulnerability, not as an abstract and immutable characteristic.

Areas to monitor are:

• digestive tolerability and possible side effects;
• pregnancy and sensitive populations;
• interactions with therapies or pre-existing conditions;
• limits of prolonged use and dosage;
• necessity to differentiate between food and supplemental use [34][35][14].

Research on ginger encompasses very different levels of evidence, from cellular models to clinical trials, i.e., experimental studies conducted on humans. Consequently, interpretation must be hierarchical: laboratory data help formulate biological hypotheses but are not sufficient to demonstrate effects in humans [11][13][16][19]. Clinical studies, on the other hand, offer information closer to real-world use, but often with limited samples, short duration, or heterogeneous inclusion criteria. In practice, ginger should be understood as a nutraceutical, i.e., a food or extract with potential physiological value, capable of providing consistent signals in certain areas, not as a universal solution. The value of this section lies precisely in bringing order, avoiding both excessive enthusiasm and absolute skepticism.

Meta-analyses, i.e., statistical syntheses of multiple studies, are particularly useful when trying to understand whether an effect observed in different studies tends to be replicated. In the case of ginger, the 2018 meta-analysis on T2DM, i.e., type 2 diabetes mellitus, and components of metabolic syndrome found a favorable signal on multiple metabolic parameters [9]. The systematic review and meta-analysis on inflammatory markers confirmed a reduction in CRP, hs-CRP, and TNF-a, but not in IL-6 and sICAM [3]. This aspect is clinically relevant because it suggests a selective and not indiscriminate action on systemic inflammation. A GRADE-assessed review, i.e., evaluated with the GRADE system for evidence quality, and dose-response, i.e., also focused on the relationship between dose and effect, more recently reinforced attention on possible antioxidant and anti-inflammatory effects, while maintaining a critical reading of the literature [4].

The most useful data concern the only partial consistency of the evidence. RCTs, i.e., randomized clinical trials, on type 2 diabetes, metabolic syndrome, obesity, and NAFLD, i.e., non-alcoholic fatty liver disease, often show a favorable direction, but the magnitude of the effect varies based on dose, duration, and participant characteristics [1][2][5][6][32][9]. In one study, for example, supplementation with 3 g/d for 3 months in 41 patients with T2DM, 22 in the ginger group and 19 in the placebo group, reduced glycemia, HbA1c, insulin, and HOMA-IR compared to placebo [1]. HbA1c, i.e., glycated hemoglobin, reflects the average glycemia trend in the preceding weeks, while HOMA-IR estimates insulin resistance. Another trial, also with 3 g/d for 3 months in adults with T2DM, observed improvements in glycemia, HbA1c, insulin, insulin resistance, hs-CRP, PON-1, TAC, and MDA [2]. Hs-CRP is a high-sensitivity C-reactive protein, useful as an indicator of low-grade inflammation; PON-1, i.e., paraoxonase 1, is an enzyme associated with protection against lipid oxidation; TAC, or total antioxidant capacity, measures the sum of antioxidant defenses; MDA, i.e., malondialdehyde, is a marker of oxidative stress. These data are useful because they show an effect involving both glycemic control and the oxidative-inflammatory profile. At the same time, results on weight and metabolic profile in overweight or obese adults remain more variable, and this advises against generalizing beyond the available evidence [5][7].

From a pathophysiological perspective, i.e., concerning disease mechanisms, the rationale is plausible. The main bioactive compounds of the rhizome, such as gingerols and shogaols, can influence the redox balance, i.e., the balance between oxidants and antioxidants, insulin signaling, and some pro-inflammatory pathways [11][13][19]. Data on mTOR, a protein complex that regulates cell growth and metabolism, on AMPK, a kinase that functions as an energy sensor, and on other cellular mechanisms come mainly from experimental models and should be read as biological bases, not as direct clinical confirmations [16][19][21][22][23]. In particular, attention to AMPK is important because this kinase can improve peripheral glucose utilization. Similarly, the inhibition of inflammation-related pathways can explain part of the benefit observed on biomarkers such as hs-CRP and TNF-a [4][3]. The distinction between mechanistic plausibility and clinical evidence therefore remains essential for a rigorous interpretation.

For this reason, the final message is neither celebratory nor reductive. Ginger has a broad scientific basis, with some solid areas and others still consolidating. The literature suggests potential interest as nutritional support, especially in metabolic contexts, but does not authorize interpretive shortcuts [1][2][4][11][7][9][3]. The question is not whether it "works" absolutely, but rather under what conditions, at what dose, and for which clinical endpoints, i.e., measurable health-relevant outcomes. This also determines the quality of the content for those seeking reliable information: the reader obtains a useful picture precisely because it is distinct, graded, and well-contextualized.

The most important editorial questions are:

• what science consistently says;
• how much meta-analyses and clinical trials weigh;
• which results remain preliminary;
• which myths require a prudent reading;
• how to distinguish mechanisms and human evidence [1][2][4][11][7][9][3].